Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599484 | 0.84 | SLC6A2 (0.74) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL15159760 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL33984 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL8094204 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL15154744 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL265002 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL15159761 | 0.84 | SLC6A2 (1.00) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL25273814 | 0.83 | SLC6A2 (0.72) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL2599478 | 0.83 | SLC6A2 (0.72) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B | |
| Phenmetrazine SCHEMBL121536 | 0.82 | SLC6A2 (0.96) | CHRNA7SLC6A2SLC6A3ADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | claimed |
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | CHRNA7 134/4885SLC6A2 5/4885SLC6A3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.